恒瑞医药和百济神州是国内创新药赛道两家头部公司，目前市值3400多亿，旗鼓相当。近期恒瑞医药也将登陆港交所主板，实现“A+H”两地上市。我们根据2家公司2024年/2025Q1财报，从业绩情况、境外营收占比、研发投入、管线布局、员工变化、员工薪酬与人效等方面做一个比较。1、业绩情况表：恒瑞医药和百济神州近5年营收恒瑞医药（600276）2024年实现营收279.8亿元，同比增长22.63%，实现...
Source Link恒瑞医药和百济神州是国内创新药赛道两家头部公司，目前市值3400多亿，旗鼓相当。近期恒瑞医药也将登陆港交所主板，实现“A+H”两地上市。我们根据2家公司2024年/2025Q1财报，从业绩情况、境外营收占比、研发投入、管线布局、员工变化、员工薪酬与人效等方面做一个比较。1、业绩情况表：恒瑞医药和百济神州近5年营收恒瑞医药（600276）2024年实现营收279.8亿元，同比增长22.63%，实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.